JB Capital LLC Sells 22,864 Shares of Johnson & Johnson (NYSE:JNJ)

JB Capital LLC decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 71.4% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 9,143 shares of the company’s stock after selling 22,864 shares during the quarter. JB Capital LLC’s holdings in Johnson & Johnson were worth $1,336,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. Goldstein Advisors LLC raised its position in shares of Johnson & Johnson by 26.8% in the second quarter. Goldstein Advisors LLC now owns 4,477 shares of the company’s stock valued at $654,000 after buying an additional 947 shares in the last quarter. My Legacy Advisors LLC bought a new position in Johnson & Johnson during the 2nd quarter worth $254,000. Unique Wealth Strategies LLC bought a new stake in shares of Johnson & Johnson during the 2nd quarter valued at $99,000. Arcus Capital Partners LLC grew its holdings in shares of Johnson & Johnson by 31.6% during the 2nd quarter. Arcus Capital Partners LLC now owns 3,179 shares of the company’s stock worth $465,000 after purchasing an additional 764 shares in the last quarter. Finally, DT Investment Partners LLC increased its position in shares of Johnson & Johnson by 1.1% in the second quarter. DT Investment Partners LLC now owns 64,154 shares of the company’s stock worth $9,377,000 after purchasing an additional 682 shares during the period. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 1.1 %

NYSE:JNJ traded up $1.78 on Friday, reaching $164.13. 7,093,429 shares of the stock traded hands, compared to its average volume of 7,299,449. The firm has a market capitalization of $395.01 billion, a price-to-earnings ratio of 10.23, a price-to-earnings-growth ratio of 2.63 and a beta of 0.52. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $167.78. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44. The company’s 50 day moving average is $153.92 and its 200-day moving average is $153.27.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The company had revenue of $22.45 billion for the quarter, compared to analysts’ expectations of $22.33 billion. During the same period last year, the business earned $2.80 EPS. Johnson & Johnson’s quarterly revenue was up 4.3% compared to the same quarter last year. Equities research analysts anticipate that Johnson & Johnson will post 10.07 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be given a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, August 27th. This represents a $4.96 annualized dividend and a yield of 3.02%. Johnson & Johnson’s payout ratio is 30.92%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on JNJ shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Monday, August 5th. Daiwa Capital Markets cut Johnson & Johnson from an “outperform” rating to a “neutral” rating and lowered their price target for the stock from $160.00 to $150.00 in a report on Tuesday, July 23rd. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 16th. Morgan Stanley boosted their target price on Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 18th. Finally, Sanford C. Bernstein raised their price target on shares of Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Seven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $173.21.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.